AUTHOR=Jiang Donglei , Zhang Yingshi , Wang Yinuo , Xu Fu , Liang Jun , Wang Weining 

TITLE=Diagnostic accuracy and prognostic significance of Glypican-3 in hepatocellular carcinoma: A systematic review and meta-analysis

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1012418

DOI=10.3389/fonc.2022.1012418

ISSN=2234-943X

ABSTRACT=Purpose: Glypican-3 (GPC-3) expression is abnormal in the occurrence and development of Hepatocellular carcinoma (HCC).To explore whether GPC-3 has diagnosis accuracy and prognosis significance of HCC, we did a systematic review and meta-analysis.
Method: PubMed, Embase, the Cochrane Library and China National Knowledge Infrastructure were searched with keywords of GPC-3, HCC and their MeSH terms from inception to July, 2022. We applied the hierarchical summary receiver operating characteristic model and evaluated the diagnostic value of GPC-3 alone and combination, and correlation between high and low GPC-3
expression on clinicopathological features and survival data in prognosis.
Results: Forty-one original publications with 6305 participants were included, with 25 of them providing data for diagnosis value and 18 records were eligible for providing prognosis value of GPC-3. GPC-3 alone got good diagnosis value in HCC patients when compared with healthy control, moderate diagnosis value when compared with cirrhotics patients. Besides, combination of GPC-3+AFP and GPC-3+GP73 got great diagnosis value in HCC versus cirrhosis groups, the combination of GPC-3 can also improve the diagnostic accuracy of biomarkers. Moreover, we discovered that over expression of GPC-3 was more likely found in HBV infection, late tumor stage, microvascular invasion groups; and causes shorter overall survival and disease free survival, which means poor prognosis.
Conclusion: GCP-3 could be used as a useful biomarker in HCC diagnosis and prognosis, especially in evaluated diagnostic value of combination with AFP or GP73, and forecast worse survival data of over-expression GPC-3.